ARAF
Serine/threonine-protein kinase A-Raf
As of the edition of 20 October 2026, ARAF (serine/threonine-protein kinase A-Raf, UniProt P10398) has 2 drugs tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10398
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 7
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Blood and lymph; Digestive system; Hormones; Nervous system; Immune system
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tovorafenib | Marketed | Phase 3 | Ends 2031 |
| Belvarafenib | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 5 |
The other 3 companies at ARAF
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at ARAF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.